Lower Urinary Tract Symptoms (LUTS) in Patients Treated with Tamsulosin at a Second Level Hospital in Veracruz Mexico.
Main Article Content
Abstract
In Mexico, benign prostatic hyperplasia (BPH) has been documented as one of the most frequent pathologies in men over 50 years old, being the most common benign tumor in males. Sixty-one percent of the male population present lower urinary tract symptoms (LUTS) starting at age 40, and it is estimated that 80% of these symptoms are caused by BPH. It has been observed that patients with BPH may experience an impact on their quality of life, both in their family and professional environments, BPH represents the most frequent disase in the urology service and the second Surgical procedure in our country.
Methodology: Observational, descriptive, cross-sectional, prospective study, a sample of 50 patients from the urology outpatient clinic was made and the IPSS Score instrument was applied in addition to adding an additional question in which the patient's interest in undergoing surgical treatment was sought. Descriptive and inferential statistics were performed for the variables of interest.
Conclusions: With increasing age, symptoms tend to become more severe, only 18% of patients (9 of them), with an average of 4.98 years of tamsulosin use, achieved good symptom control, reaching mild stages, Most patients continued to have moderate to severe symptoms, without achieving complete reversal of symptoms, the more severe the symptoms, the more difficult it is to achieve good control with drug treatment, and the likelihood of requiring surgical treatment increases, Although most patients express interest in undergoing transurethral resection of the prostate (TURP), there are barriers such as myths, fear, and indifference that limit acceptance of the surgery.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Guess HA, Arrighi HM, Metter EJ, Fozard JL. La prevalencia acumulada de prostatismo coincide con la prevalencia de hiperplasia prostática benigna en autopsias. Próstata. 1990;17:241–246. doi: 10.1002/pros.2990170308.
II. Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR. Prevalencia, gravedad y correlaciones con la salud de los síntomas del tracto urinario inferior en hombres mayores: el estudio MrOS. Urología. 2006; 68:804–809. doi: 10.1016/j.urology.2006.04.019
III. Fowke JH, Phillips S., Koyama T., Byerly S., Concepcion R., Motley SS. Asociación entre la actividad física, los síntomas del tracto urinario inferior (STUI) y el volumen prostático. BJU Int. 2013;111:122–128.
doi: 10.1111/j.1464-410X.2012.11287
IV. Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian Journal of Urology. 2017;4(3):148–151
V. Dunn, C. J., Matheson, A., & Faulds, D. M. (2002). Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs & Aging, 19(2), 135–161. PubMed
VI. Perinchery Narayan, M., & Tunuguntla, H. S. G. R. (2005). Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia. Reviews in Urology, 7(Suppl 4), S42–S48. journals.specialtynetworks.com PMC Medical therapy for benign prostatic hyperplasia: a review of the literature. (s. f.). PubMed. PubMed
VII. López Ramos, H. E., Medina-Rico, M., Bastidas Rosas, D., & Lara, B. (2018, 30 de agosto). Tratamiento farmacológico de la hiperplasia prostática benigna. Revisión de la bibliografía. Revista Mexicana de Urología.
https://doi.org/10.48193/revistamexicanadeurologa.v78i4.96
VIII. Eficacia en atención primaria: Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting. (s. f.). PubMed.
IX. Roehrborn, C. G., Siami, P., Barkin, J., Damião, R., Becher, E., Miñana, B., Mirone, V., Castro, R., Wilson, T., & Montorsi, F. (2009). The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year post hoc analysis of European men in the CombAT study. European Urology, 55(2), 461–471. https://doi.org/10.1016/j.eururo.2008.10.037 PubMed
X. Becher, E., Roehrborn, C. G., Siami, P., et al. (2009). The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin (CombAT) study. Prostate Cancer and Prostatic Diseases, 12, 369–374. https://doi.org/10.1038/pcan.2009.37 Nature
XI. Montorsi, F., Roehrborn, C. G., Garcia-Penit, J., et al. (2011). The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU International, 107(9), 1426–1431.
https://doi.org/10.1111/j.1464-410X.2011.10129.x bjui-journals.onlinelibrary.wiley.com
XII. Barkin, J., Roehrborn, C. G., Siami, P., Haillot, O., Morrill, B., Black, L., & Montorsi, F.; CombAT Study Group. (2009). Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU International, 103(7), 919–926.
https://doi.org/10.1111/j.1464-410X.2009.08196.x bjui-journals.onlinelibrary.wiley.com
XIII. Roehrborn, C. G., Oyarzabal Perez, I., Roos, E. P., Calomfirescu, N., Brotherton, B., Palacios, J. M., & Manyak, M. J. (2017). Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study. World Journal of Urology, 35(3), 421–427.
https://doi.org/10.1007/s00345-016-1884-5 PubMed
XIV. Greco, K. A., & McVary, K. T. (2008). The role of combination medical therapy in benign prostatic hyperplasia. International Journal of Impotence Research, 20(Suppl 3), S33–S43. https://doi.org/10.1038/ijir.2008.51 PubMed
XV. Naslund, M. J., & Miner, M. (2007). A review of the clinical efficacy and safety of 5-alpha-reductase inhibitors for the enlarged prostate. Clinical Therapeutics, 29(1), 17–25.
https://doi.org/10.1016/j.clinthera.2007.01.018 PubMed
XVI. Park, T., & Choi, J. Y. (2014). Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. World Journal of Urology, 32(4), 1093–1105.
https://doi.org/10.1007/s00345-014-1258-9 PubMed
XVII. Keating, G. M. (2012). Dutasteride/tamsulosin: in benign prostatic hyperplasia. Drugs & Aging, 29(5), 405–419. https://doi.org/10.2165/11208920-000000000-00000 PubMed
XVIII. Masumori N, Tsukamoto T, Horita H, Sunaoshi K, Tanaka Y, Takeyama K, Sato E, Miyao N. α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study. Int J Urol. 2013 Apr;20(4):421-8. doi: 10.1111/j.1442-2042.2012.03165.x. Epub 2012 Sep 19. PMID: 22989348.
XIX. Review article (2015): Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart®) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve... 2-year CONDUCT study results. BJU International. Roehrborn, C. G., et al. (2015).
https://doi.org/10.1111/bju.13033
XX. Lokeshwar, S. D., Harper, B. T., Webb, E., Jordan, A., Dykes, T. A., Neal Jr., D. E., Terris, M. K., & Klaassen, Z. (2019). Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Translational Andrology and Urology, 8(5), 529–539.